Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$1.39 | -$1.27 | -$1.33 |
| Q2 2026 | 2 | -$0.87 | -$0.68 | -$0.78 |
| Q3 2026 | 2 | -$0.66 | -$0.52 | -$0.59 |
| Q4 2026 | 1 | -$0.58 | -$0.58 | -$0.58 |
| Q1 2027 | 1 | -$0.77 | -$0.77 | -$0.77 |
| Q2 2027 | 1 | -$0.73 | -$0.73 | -$0.73 |
| Q3 2027 | 1 | -$0.78 | -$0.78 | -$0.78 |
| Q4 2027 | 1 | -$0.87 | -$0.87 | -$0.87 |
| Q1 2028 | 1 | -$0.93 | -$0.93 | -$0.93 |
| Q2 2028 | 1 | -$0.88 | -$0.88 | -$0.88 |
| Q3 2028 | 1 | -$0.95 | -$0.95 | -$0.95 |
| Q4 2028 | 1 | -$1.05 | -$1.05 | -$1.05 |
FibroBiologics Inc last posted its earnings results on Thursday, April 30th, 2026. The company reported $-1.33 earnings per share for the quarter, missing analysts' consensus estimates of $-1.26 by $0.07. The company had revenue of 0 for the quarter and had revenue of 0 for the year. FibroBiologics Inc has generated $-8 earnings per share over the last year ($-8.4 diluted earnings per share) and currently has a price-to-earnings ratio of -0.14. FibroBiologics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 04/30/2026 | Q1 2026 | -$1.26 | -$2.24 | -0.98 | $0 | $0 |
| 02/24/2026 | Q4 2025 | -$1.44 | -$0.98 | 0.46 | $0 | $0 |
| 10/31/2025 | Q3 2025 | -$0.10 | -$2.60 | -2.5 | $0 | $0 |
| 07/31/2025 | Q2 2025 | -$0.11 | -$2.40 | -2.29 | N/A | $0 |
| 05/14/2025 | Q1 2025 | N/A | -$2.80 | N/A | N/A | $0 |
| 03/31/2025 | Q4 2024 | -$0.10 | -$1.78 | -1.68 | N/A | $0 |
| 11/12/2024 | Q3 2024 | -$0.08 | -$0.20 | -0.12 | N/A | $0 |
| 06/28/2024 | Q2 2024 | N/A | $0.60 | N/A | N/A | $0 |
| 03/30/2024 | Q1 2024 | N/A | -$5.40 | N/A | N/A | $0 |
| 12/30/2023 | Q4 2023 | N/A | -$6.20 | N/A | N/A | $0 |
| 09/29/2023 | Q3 2023 | N/A | -$1.35 | N/A | N/A | $0 |
| 06/29/2023 | Q2 2023 | N/A | -$1.33 | N/A | N/A | $0 |
| 03/30/2023 | Q1 2023 | N/A | -$3.00 | N/A | N/A | $0 |
| 12/30/2022 | Q4 2022 | N/A | -$1.00 | N/A | N/A | $0 |
| 09/28/2022 | Q3 2022 | N/A | -$1.03 | N/A | N/A | $0 |
| 06/30/2022 | Q2 2022 | N/A | -$0.72 | N/A | N/A | $0 |
| 03/31/2022 | Q1 2022 | N/A | -$0.72 | N/A | N/A | $0 |
The conference call for FibroBiologics Inc's latest earnings report can be listened to online.
The conference call transcript for FibroBiologics Inc's latest earnings report can be read online.
FibroBiologics Inc (:FBLG) has a recorded net income of $-18,646,000.FibroBiologics Inc has generated $-8.4 earnings per share over the last four quarters.
FibroBiologics Inc (:FBLG) has a price-to-earnings ratio of -0.14 and price/earnings-to-growth ratio is 0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED